PL3458083T3 - Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania - Google Patents

Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania

Info

Publication number
PL3458083T3
PL3458083T3 PL17726458.7T PL17726458T PL3458083T3 PL 3458083 T3 PL3458083 T3 PL 3458083T3 PL 17726458 T PL17726458 T PL 17726458T PL 3458083 T3 PL3458083 T3 PL 3458083T3
Authority
PL
Poland
Prior art keywords
polynucleotides encoding
encoding interleukin
interleukin
polynucleotides
encoding
Prior art date
Application number
PL17726458.7T
Other languages
English (en)
Inventor
Joshua Frederick
Susannah HEWITT
Ailin Bai
Stephen Hoge
Vladimir PRESNYAK
Iain Mcfadyen
Kerry BENENATO
Ellalahewage Sathyajith Kumarasinghe
Original Assignee
Modernatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794205&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3458083(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Modernatx, Inc. filed Critical Modernatx, Inc.
Publication of PL3458083T3 publication Critical patent/PL3458083T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL17726458.7T 2016-05-18 2017-05-18 Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania PL3458083T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662338483P 2016-05-18 2016-05-18
US201762443693P 2017-01-07 2017-01-07
PCT/US2017/033422 WO2017201350A1 (en) 2016-05-18 2017-05-18 Polynucleotides encoding interleukin-12 (il12) and uses thereof

Publications (1)

Publication Number Publication Date
PL3458083T3 true PL3458083T3 (pl) 2023-03-13

Family

ID=58794205

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17726458.7T PL3458083T3 (pl) 2016-05-18 2017-05-18 Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania

Country Status (22)

Country Link
US (5) US10646549B2 (pl)
EP (2) EP4186518A1 (pl)
JP (2) JP7246930B2 (pl)
KR (2) KR20220159479A (pl)
CN (1) CN109195621A (pl)
AU (1) AU2017268397B2 (pl)
CA (1) CA3024470A1 (pl)
DK (1) DK3458083T3 (pl)
ES (1) ES2941411T3 (pl)
FI (1) FI3458083T3 (pl)
HR (1) HRP20230050T1 (pl)
HU (1) HUE061077T2 (pl)
IL (1) IL262501A (pl)
LT (1) LT3458083T (pl)
MX (2) MX2018013509A (pl)
PL (1) PL3458083T3 (pl)
PT (1) PT3458083T (pl)
RS (1) RS63912B1 (pl)
RU (1) RU2769316C2 (pl)
SG (1) SG11201809381XA (pl)
SI (1) SI3458083T1 (pl)
WO (1) WO2017201350A1 (pl)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
RS63030B1 (sr) 2015-09-17 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
MD3718565T2 (ro) 2015-10-22 2022-09-30 Modernatx Inc Vaccinuri împotriva virusului respirator
CA3007297A1 (en) 2015-12-22 2017-06-29 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
LT3458083T (lt) 2016-05-18 2023-02-10 Modernatx, Inc. Polinukleotidai, koduojantys interleukiną-12 (il12), ir jų naudojimas
EP3538067A1 (en) 2016-11-08 2019-09-18 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP3551193A4 (en) * 2016-12-08 2020-08-19 Modernatx, Inc. NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
EP3596042B1 (en) 2017-03-15 2022-01-12 Modernatx, Inc. Crystal forms of amino lipids
KR20190132405A (ko) 2017-03-15 2019-11-27 모더나티엑스, 인크. 치료제의 세포내 전달을 위한 화합물 및 조성물
EP3595727A1 (en) 2017-03-15 2020-01-22 ModernaTX, Inc. Lipid nanoparticle formulation
WO2018187590A1 (en) 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
CN111212905A (zh) 2017-08-18 2020-05-29 摩登纳特斯有限公司 Rna聚合酶变体
MA49922A (fr) 2017-08-18 2021-06-02 Modernatx Inc Procédés pour analyse par clhp
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
WO2019232160A1 (en) * 2018-05-31 2019-12-05 Beth Israel Deaconess Medical Center Rna-aided immunotherapeutics
CA3100276A1 (en) 2018-06-06 2019-12-12 Massachusetts Institute Of Technology Circular rna for translation in eukaryotic cells
GB2617429B (en) 2018-09-04 2023-12-27 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
GB2617430B (en) 2018-09-04 2023-12-27 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
AU2019338535A1 (en) * 2018-09-14 2021-04-15 Modernatx, Inc. Methods and compositions for treating cancer using mRNA therapeutics
KR102524247B1 (ko) * 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3의 복합체 및 이의 용도
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
US11026894B2 (en) 2019-01-10 2021-06-08 Massachusetts Institute Of Technology Lipid nanoparticles and use thereof to deliver RNA polynucleotides
US20220395584A1 (en) * 2019-03-14 2022-12-15 Engene, Inc Reversible coating of chitosan-nucleic acid nanoparticles and methods of their use
CN109932511B (zh) * 2019-03-22 2020-02-04 南昌大学第二附属医院 用于肝癌筛查的尿液外泌体磷脂标志物及其试剂盒
US20200325241A1 (en) * 2019-04-11 2020-10-15 Massachusetts Institute Of Technology Novel chimeric antigen receptors and libraries
SG11202112922WA (en) 2019-05-22 2021-12-30 Massachusetts Inst Technology Circular rna compositions and methods
BR112022004759A2 (pt) 2019-09-19 2022-06-21 Modernatx Inc Composições e compostos lipídicos com cauda ramificada para entrega intracelular de agentes terapêuticos
PE20221182A1 (es) 2019-11-18 2022-08-05 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
EP3920976B1 (en) 2019-12-04 2023-07-19 Orna Therapeutics, Inc. Circular rna compositions and methods
CA3168509A1 (en) * 2020-02-19 2021-08-26 Elias SAYOUR Multilamellar rna nanoparticles and methods of sensitizing tumors to treatment with immune checkpoint inhibitors
WO2021168405A1 (en) 2020-02-21 2021-08-26 Combined Therapeutics, Inc. Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
BR112022020203A2 (pt) 2020-04-09 2022-11-22 Suzhou Abogen Biosciences Co Ltd Composição de nanopartículas lipídicas
EP4132576A1 (en) 2020-04-09 2023-02-15 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for coronavirus
WO2021233849A1 (en) 2020-05-17 2021-11-25 Boehringer Ingelheim International Gmbh Viral vectors and nucleic acids for regulated gene therapy
JP2023535225A (ja) 2020-07-24 2023-08-16 ストランド セラピューティクス インコーポレイテッド 改変ヌクレオチドを含む脂質ナノ粒子
AR124599A1 (es) 2021-01-08 2023-04-12 Strand Therapeutics Inc Constructos de expresión y usos de estos
US11524023B2 (en) * 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same
CN113509542A (zh) * 2021-04-20 2021-10-19 嘉晨西海(杭州)生物技术有限公司 一种基于mRNA的表达白介素12针对肿瘤的药物及其制备方法
AU2022268465A1 (en) * 2021-05-06 2023-03-09 Stemirna Therapeutics Co., Ltd. A lipid
CA3230031A1 (en) 2021-09-03 2023-03-09 Patrick Baumhof Novel lipid nanoparticles for delivery of nucleic acids
WO2023056915A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Polynucleotides encoding interleukin-12 (il-12) and related composition and methods thereof
WO2023073228A1 (en) 2021-10-29 2023-05-04 CureVac SE Improved circular rna for expressing therapeutic proteins
CN116179549A (zh) 2021-12-08 2023-05-30 南京吉迈生物技术有限公司 通过5’utr序列变体修饰基因转录和翻译效率
CN114957027B (zh) * 2022-01-13 2023-05-19 北京悦康科创医药科技股份有限公司 一种阳离子脂质化合物、包含其的组合物及用途
WO2023144330A1 (en) 2022-01-28 2023-08-03 CureVac SE Nucleic acid encoded transcription factor inhibitors
WO2023196988A1 (en) * 2022-04-07 2023-10-12 Modernatx, Inc. Methods of use of mrnas encoding il-12
CN116535491B (zh) * 2022-05-06 2024-03-22 珠海丽凡达生物技术有限公司 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用
CN114994331B (zh) * 2022-05-17 2023-02-24 无锡科金生物科技有限公司 一种检测蛋白表达水平的试剂盒及其制备方法和应用
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide
US20240156949A1 (en) 2022-10-28 2024-05-16 Glaxosmithkline Biologicals Sa Nucleic Acid Based Vaccine
WO2024098360A1 (zh) * 2022-11-11 2024-05-16 斯微(上海)生物科技股份有限公司 人工核酸分子

Family Cites Families (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5082767A (en) 1989-02-27 1992-01-21 Hatfield G Wesley Codon pair utilization
US6140496A (en) 1990-10-09 2000-10-31 Benner; Steven Albert Precursors for deoxyribonucleotides containing non-standard nucleosides
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5922685A (en) 1996-06-05 1999-07-13 Powderject Vaccines, Inc. IL-12 gene therapy of tumors
CA2268276A1 (en) 1996-10-18 1998-04-30 Jeff Nordstrom Gene expression and delivery systems and uses
US5994104A (en) 1996-11-08 1999-11-30 Royal Free Hospital School Of Medicine Interleukin-12 fusion protein
JP2001521759A (ja) 1997-11-12 2001-11-13 ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド ヒトアミロイド前駆体タンパク質遺伝子の翻訳エンハンサーエレメント
JP2001523480A (ja) 1997-11-20 2001-11-27 バイカル インコーポレイテッド サイトカイン発現ポリヌクレオチドおよびそれらの組成物を用いた癌の処置
US7521178B1 (en) 1998-04-23 2009-04-21 Takara Bio Inc. Method for synthesizing DNA
EP1030680A4 (en) 1998-09-15 2003-05-02 Genetics Inst TREATMENT OF CAPOSISARCOMA WITH IL-12
WO2000018778A1 (en) 1998-09-29 2000-04-06 Phylos, Inc. Synthesis of codon randomized nucleic acids
EP1792991A1 (en) 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1248654B1 (en) 2000-01-20 2005-10-05 Universität Zürich Institut für Medizinische Virologie Intra-tumoral administration of il-12 encoding naked nucleic acid molecules
US7468275B2 (en) 2000-01-28 2008-12-23 The Scripps Research Institute Synthetic internal ribosome entry sites and methods of identifying same
BR0107943A (pt) 2000-01-28 2003-01-28 Scripps Research Inst Sìtios de entrada de ribossoma internos sintéticos e métodos de identificar os mesmos
ES2164011B1 (es) 2000-02-25 2003-05-16 Inst Cientifico Tecnol Navarra Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos.
WO2001068802A2 (en) 2000-03-15 2001-09-20 Pohang University Of Science And Technology Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant
KR20020010206A (ko) 2000-07-27 2002-02-04 이시우 인터루킨 12와 보조활성인자 ｂ7.1 유전자를 함유하는ｄｎａ 벡터 및 이벡터가 도입된 항암 세포백신
ATE464317T1 (de) 2001-06-05 2010-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt für die gentherapie
WO2003004685A2 (en) 2001-07-03 2003-01-16 University Of Utah Research Foundation Soluble steroidal peptides for nucleic acid delivery
EP2385122B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
WO2003042383A1 (fr) 2001-11-14 2003-05-22 Toyo Boseki Kabushiki Kaisha Promoteurs de replication de l'adn, facteurs associes a l'adn polymerase et utilisation de ces derniers
CA2409775C (en) 2001-12-03 2010-07-13 F. Hoffmann-La Roche Ag Reversibly modified thermostable enzymes for dna synthesis and amplification in vitro
CA2480504A1 (en) 2002-04-01 2003-10-16 Evelina Angov Method of designing synthetic nucleic acid sequences for optimal protein expression in a host cell
US7595303B1 (en) 2002-09-05 2009-09-29 University Of South Florida Genetic adjuvants for immunotherapy
DE10248141B4 (de) 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
DE10260805A1 (de) 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
EA200501937A1 (ru) 2003-05-30 2006-08-25 Университет Южной Флориды Способ лечения злокачественных опухолей
EP2530157B1 (en) 2003-07-31 2016-09-28 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of miRNAs
GB0329146D0 (en) 2003-12-16 2004-01-21 Glaxosmithkline Biolog Sa Vaccine
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
EP1640018A1 (en) 2004-09-24 2006-03-29 Universität Zürich Combinational therapy for treating cancer
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
US7550264B2 (en) 2005-06-10 2009-06-23 Datascope Investment Corporation Methods and kits for sense RNA synthesis
US8105813B2 (en) 2005-06-30 2012-01-31 Archemix Corp. Materials and methods for the generation of fully 2′-modified nucleic acid transcripts
US8101385B2 (en) 2005-06-30 2012-01-24 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
RS63964B1 (sr) 2005-08-23 2023-03-31 Univ Pennsylvania Rnk koja sadrži modifikovane nukleozide i postupci za njenu upotrebu
EP1934329B1 (en) 2005-08-24 2016-11-02 The Scripps Research Institute Translation enhancer-element dependent vector systems
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
PT1966238E (pt) 2005-12-30 2012-07-31 Merck Patent Gmbh Uso de hsp70 como um regulador de atividade enzimática
EP1969147B1 (en) 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
US7670840B2 (en) 2006-01-05 2010-03-02 The Ohio State University Research Foundation Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors
WO2007084364A2 (en) 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Improved il-12 for expression in mammalian cells
KR101241477B1 (ko) 2006-01-27 2013-03-08 엘지이노텍 주식회사 질화물 반도체 발광소자 및 그 제조 방법
EP1991706B1 (en) 2006-03-02 2014-01-15 The Ohio State University Research Foundation Microrna expression profile associated with pancreatic cancer
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US20080046192A1 (en) 2006-08-16 2008-02-21 Richard Lathrop Polypepetide-encoding nucleotide sequences with refined translational kinetics and methods of making same
CA2664383C (en) 2006-09-19 2017-08-22 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
DE102006051516A1 (de) 2006-10-31 2008-05-08 Curevac Gmbh (Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
AU2007314212B2 (en) 2006-11-01 2014-05-29 The Govt. Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services MicroRNA expression signature for predicting survival and metastases in Hepatocellular carcinoma
CN101627121A (zh) 2006-12-08 2010-01-13 奥斯瑞根公司 作为治疗干预的靶标的miRNA调控基因和路径
WO2008078180A2 (en) 2006-12-22 2008-07-03 Archemix Corp. Materials and methods for the generation of transcripts comprising modified nucleotides
EP3293266A1 (en) 2007-05-04 2018-03-14 University Health Network Il-12 immunotherapy for cancer
WO2008147974A1 (en) 2007-05-23 2008-12-04 University Of South Florida Micro-rnas modulating immunity and inflammation
WO2008154098A2 (en) 2007-06-07 2008-12-18 Wisconsin Alumni Research Foundation Reagents and methods for mirna expression analysis and identification of cancer biomarkers
PL2170959T3 (pl) 2007-06-18 2014-03-31 Merck Sharp & Dohme Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
TWI359030B (en) 2007-08-24 2012-03-01 Univ Nat Taiwan Treatment of cellular proliferative disorders
HUE029164T2 (hu) 2007-09-14 2017-02-28 Univ Brussel Vrije Humán antigén-prezentáló sejtek T-sejteket stimuláló képességének fokozása és azok alkalmazása vakcinázásra
WO2009039198A2 (en) 2007-09-17 2009-03-26 The Trustees Of The University Of Pennsylvania Generation of hyperstable mrnas
EP2205282A2 (en) * 2007-09-24 2010-07-14 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
CA2715078C (en) 2007-09-26 2019-07-23 Intrexon Corporation Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression
JP2011505143A (ja) 2007-11-30 2011-02-24 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション マイクロｒｎａ発現プロファイリング及び肺癌における末梢血ターゲティング
SG10201408162PA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
JP5749494B2 (ja) * 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション 核酸の送達のための改善された組成物および方法
EP2260110B1 (en) 2008-02-08 2014-11-12 Asuragen, INC. miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
WO2009108856A2 (en) 2008-02-28 2009-09-03 The Ohio State University Research Foundation Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof
DK2279254T3 (en) * 2008-04-15 2017-09-18 Protiva Biotherapeutics Inc PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
WO2009140206A1 (en) 2008-05-11 2009-11-19 The Gov. Of The U. S. A., As Represented By The Secretary Of The Dept. Of Health And Human Services Improved expression of il-12 family heterodimers
US8126653B2 (en) 2008-07-31 2012-02-28 Dna Twopointo, Inc. Synthetic nucleic acids for expression of encoded proteins
US7561973B1 (en) 2008-07-31 2009-07-14 Dna Twopointo, Inc. Methods for determining properties that affect an expression property value of polynucleotides in an expression system
US8401798B2 (en) 2008-06-06 2013-03-19 Dna Twopointo, Inc. Systems and methods for constructing frequency lookup tables for expression systems
PL215513B1 (pl) 2008-06-06 2013-12-31 Univ Warszawski Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka
WO2009149539A1 (en) 2008-06-10 2009-12-17 Université de Montréal Enhancing antigen-specific cd8+ t cell response using irf-7 mrna
WO2010018563A2 (en) 2008-08-12 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for the prognosis of lymphoma
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
CN102439169B (zh) 2008-11-13 2014-11-19 复旦大学 用于结肠直肠癌的微rna表达谱分析的组合物和方法
KR20210060670A (ko) 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
EP2358902A1 (en) 2008-12-10 2011-08-24 Universität Regensburg Compositions and methods for micro-rna expression profiling of cancer stem cells
WO2010126766A1 (en) * 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
EP2427574A2 (en) 2009-05-08 2012-03-14 The Ohio State University Research Foundation Microrna expression profiling and targeting in chronic obstructive pulmonary disease (copd) lung tissue and methods of use thereof
TR201811076T4 (tr) 2009-06-10 2018-08-27 Arbutus Biopharma Corp Geliştirilmiş lipit formulasyonu.
CA2769670C (en) 2009-07-31 2018-10-02 Ethris Gmbh Rna with a combination of unmodified and modified nucleotides for protein expression
EP2281579A1 (en) 2009-08-05 2011-02-09 BioNTech AG Vaccine composition comprising 5'-Cap modified RNA
US20110082055A1 (en) 2009-09-18 2011-04-07 Codexis, Inc. Reduced codon mutagenesis
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
DK3338765T3 (en) 2009-12-01 2019-03-04 Translate Bio Inc STEROID DERIVATIVE FOR THE SUPPLY OF MRNA IN HUMANGENETIC DISEASES
WO2011076142A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expession profiling in plasma of colorectal cancer
WO2011076143A1 (en) 2009-12-24 2011-06-30 Fudan University Compositions and methods for microrna expression profiling of lung cancer
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2011094683A2 (en) 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of identifying myelodysplastic syndromes
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
US20130059015A1 (en) 2010-03-11 2013-03-07 H. Lee Moffitt Cancer Center & Research Institute Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response
WO2011157294A1 (en) 2010-06-16 2011-12-22 Universita' Degli Studi Di Padova Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
US20130230884A1 (en) 2010-07-16 2013-09-05 John Chaput Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation
WO2012038448A1 (en) 2010-09-21 2012-03-29 Riboxx Gmbh Method for synthesizing rna using dna template
WO2012072096A1 (en) 2010-12-03 2012-06-07 Biontech Ag Method for cellular rna expression
KR20120066952A (ko) 2010-12-15 2012-06-25 주식회사 롤팩 7층 구조의 공압출 항균 진공포장 필름 및 그 제조방법
WO2012103985A2 (en) 2010-12-16 2012-08-09 Steve Pascolo Pharmaceutical composition consisting of rna having alkali metal as counter ion and formulated with dications
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US20140113978A1 (en) 2011-05-01 2014-04-24 University Of Rochester Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof
WO2012150807A2 (ko) 2011-05-02 2012-11-08 엘지전자 주식회사 무선 접속 시스템에서 데이터 송수신 방법 및 이를 위한 기지국
EP2944961A1 (en) 2011-05-06 2015-11-18 XenTech Markers for cancer prognosis and therapy and methods of use
PL2717893T3 (pl) 2011-06-08 2019-12-31 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby do dostarczania mRNA
US20140272998A1 (en) 2011-07-15 2014-09-18 Leo Pharma A/S Diagnostic microrna profiling in cutaneous t-cell lymphoma (ctcl)
EP2751292A4 (en) 2011-09-01 2015-05-20 Allegro Diagnostics Corp METHOD AND COMPOSITIONS FOR DETECTING CANCER BASED ON MIRNA EXPRESSION PROFILES
EP2755986A4 (en) 2011-09-12 2015-05-20 Moderna Therapeutics Inc MODIFIED NUCLEIC ACIDS AND METHODS OF USE
ES2911677T3 (es) 2011-10-03 2022-05-20 Modernatx Inc Nucleósidos, nucleótidos y ácidos nucleicos modificados, y sus usos
US20150017121A1 (en) 2011-10-11 2015-01-15 Universitat Zurich Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
WO2013066678A1 (en) 2011-10-26 2013-05-10 Georgetown University Microrna expression profiling of thyroid cancer
CA2856895C (en) 2011-11-28 2021-10-26 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
KR102101819B1 (ko) 2011-12-12 2020-04-21 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 개선된 il-12 유전적 컨스트럭트 및 백신을 포함하는 조성물, 면역치료제 및 이를 이용하는 방법
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US20140010861A1 (en) 2012-04-02 2014-01-09 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
CN104470949A (zh) 2012-05-15 2015-03-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
EP2672197A1 (de) 2012-06-06 2013-12-11 Hörmann Energietechnik GmbH & Co. KG Montageanordnung zur dachseitigen Montage von Flächenkörpern an einem Bauwerk
WO2013185069A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Pulmonary delivery of mrna to non-lung target cells
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
US20140020675A1 (en) 2012-07-18 2014-01-23 Chandrashekhar Sonwane Solar receiver
EP2885419A4 (en) 2012-08-14 2016-05-25 Moderna Therapeutics Inc ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
CN102876684B (zh) * 2012-09-17 2014-10-08 青岛康立泰药业有限公司 人白细胞介素-12的编码基因、真核宿主细胞和表达方法
US20150307542A1 (en) 2012-10-03 2015-10-29 Moderna Therapeutics, Inc. Modified nucleic acid molecules and uses thereof
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
LT2922554T (lt) * 2012-11-26 2022-06-27 Modernatx, Inc. Terminaliai modifikuota rnr
WO2014089486A1 (en) 2012-12-07 2014-06-12 Shire Human Genetic Therapies, Inc. Lipidic nanoparticles for mrna delivering
AU2013374345A1 (en) 2013-01-17 2015-08-06 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
RU2718988C2 (ru) 2013-02-22 2020-04-15 Куревак Аг Комбинация противораковой рнк-вакцины и ингибитора пути pd-1 и ее применение
EA030650B1 (ru) 2013-03-08 2018-09-28 Новартис Аг Липиды и липидные композиции для доставки активных агентов
EP2964234A4 (en) 2013-03-09 2016-12-07 Moderna Therapeutics Inc NON-TRANSLATED HETEROLOGOUS REGIONS FOR MRNA
SI2970456T1 (sl) 2013-03-14 2022-01-31 Translate Bio, Inc. Postopki in sestavki za dostavo MRNA-kodiranih protiteles
EP3431592A1 (en) 2013-03-14 2019-01-23 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
AU2014239264A1 (en) 2013-03-14 2015-08-27 Shire Human Genetic Therapies, Inc. Quantitative assessment for cap efficiency of messenger RNA
ES2689523T3 (es) 2013-03-14 2018-11-14 Translate Bio, Inc. Composiciones a base de ARNM del gen CFTR y métodos y usos relacionados
ES2797974T3 (es) 2013-03-14 2020-12-04 Translate Bio Inc Acidos ribonucleicos con nucleótidos modificados con 4-tio y procedimientos relacionados
BR112015022660A2 (pt) 2013-03-14 2017-10-31 Shire Human Genetic Therapies métodos para a purificação de rna mensageiro
EA201591283A1 (ru) 2013-03-14 2016-02-29 Шир Хьюман Дженетик Терапис, Инк. Количественная оценка эффективности кэп матричной рнк
DK2972360T3 (en) 2013-03-15 2018-05-22 Translate Bio Inc SYNERGISTIC IMPROVEMENT OF DELIVERY OF NUCLEIC ACIDS THROUGH MIXED FORMULATIONS
ES2702466T3 (es) 2013-08-21 2019-03-01 Curevac Ag Procedimiento para aumentar la expresión de proteínas codificadas por ARN
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
EP3053592A4 (en) 2013-10-01 2017-09-06 Mie University T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
CA2927393A1 (en) 2013-10-18 2015-04-23 Moderna Therapeutics, Inc. Compositions and methods for tolerizing cellular systems
CN105813656B (zh) 2013-10-22 2021-01-15 夏尔人类遗传性治疗公司 用于递送信使rna的脂质制剂
EA201992208A1 (ru) 2013-10-22 2020-07-31 Транслейт Био, Инк. ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
ES2806575T3 (es) 2013-11-01 2021-02-18 Curevac Ag ARN modificado con propiedades inmunoestimuladoras disminuidas
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
JP2017501712A (ja) * 2013-12-18 2017-01-19 イントレキソン コーポレーション 単鎖ｉｌ−１２核酸、ポリペプチド、およびそれらの使用
CN105874072A (zh) 2013-12-30 2016-08-17 库瑞瓦格股份公司 人工核酸分子
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
PT3134131T (pt) * 2014-04-23 2022-03-24 Modernatx Inc Vacinas de ácidos nucleicos
SI3766916T1 (sl) * 2014-06-25 2023-01-31 Acuitas Therapeutics Inc. Formulacije novih lipidov in lipidnih nanodelcev za dostavo nukleinskih kislin
CA2962099A1 (en) 2014-09-22 2016-03-31 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
ES2746340T3 (es) 2015-04-22 2020-03-05 Curevac Ag Composición que contiene ARN para el tratamiento de enfermedades tumorales
US10682401B2 (en) 2015-05-19 2020-06-16 Morphogenesis, Inc. Multi-indication mRNA cancer immunotherapy
EP3297664B1 (en) 2015-05-19 2020-11-18 Morphogenesis, Inc. Cancer vaccine comprising mrna encoding a m-like-protein
RS63030B1 (sr) 2015-09-17 2022-04-29 Modernatx Inc Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava
EP3205356A1 (en) 2016-02-10 2017-08-16 Onkoloski Institut Ljubljana Plasmid expression vector encoding human interleukin 12 under transcriptional control of p21 promoter and without antibiotic resistance for cancer gene therapy and other uses thereof
EP3211000B1 (en) 2016-02-25 2019-01-30 Provecs Medical GmbH Novel immunostimulating vector system
LT3458083T (lt) 2016-05-18 2023-02-10 Modernatx, Inc. Polinukleotidai, koduojantys interleukiną-12 (il12), ir jų naudojimas
MX2019001920A (es) 2016-08-19 2019-07-01 Curevac Ag Arn la terapia contra el cancer.
CN110267978A (zh) 2016-10-07 2019-09-20 得克萨斯大学体系董事会 用于治疗癌症的表达膜锚定的il-12的t细胞

Also Published As

Publication number Publication date
US20190125839A1 (en) 2019-05-02
US20240024422A1 (en) 2024-01-25
JP2023072056A (ja) 2023-05-23
FI3458083T3 (fi) 2023-03-01
RU2769316C2 (ru) 2022-03-30
KR102469450B1 (ko) 2022-11-22
JP7246930B2 (ja) 2023-03-28
RS63912B1 (sr) 2023-02-28
KR20220159479A (ko) 2022-12-02
WO2017201350A1 (en) 2017-11-23
KR20190008890A (ko) 2019-01-25
US10646549B2 (en) 2020-05-12
SG11201809381XA (en) 2018-12-28
US20210299221A1 (en) 2021-09-30
MX2022008602A (es) 2022-08-11
US11311602B2 (en) 2022-04-26
EP3458083A1 (en) 2019-03-27
EP4186518A1 (en) 2023-05-31
CN109195621A (zh) 2019-01-11
RU2018144292A (ru) 2020-06-18
AU2017268397A1 (en) 2019-01-17
US11000573B2 (en) 2021-05-11
EP3458083B1 (en) 2022-11-02
US20220265774A1 (en) 2022-08-25
AU2017268397B2 (en) 2023-07-06
HRP20230050T1 (hr) 2023-03-03
ES2941411T3 (es) 2023-05-22
RU2018144292A3 (pl) 2021-03-10
LT3458083T (lt) 2023-02-10
US20200376081A1 (en) 2020-12-03
MX2018013509A (es) 2019-03-28
IL262501A (en) 2018-12-31
CA3024470A1 (en) 2017-11-23
SI3458083T1 (sl) 2023-03-31
DK3458083T3 (da) 2023-01-30
HUE061077T2 (hu) 2023-05-28
JP2019516710A (ja) 2019-06-20
US11571463B2 (en) 2023-02-07
PT3458083T (pt) 2023-03-06

Similar Documents

Publication Publication Date Title
IL262501A (en) Polynucleotides encoding interleukin-12 (il12) and their uses
IL264475A (en) A versatile training device
ZA201900737B (en) Xylanase variants and polynucleotides encoding same
ZA201803706B (en) Enzyme variants and polynucleotides encoding the same
HUE047519T2 (hu) Paletta blokkméretének korlátozása video kódolásban
IL293377B1 (en) Variants of hsd17b13 and their uses
HK1254696A1 (zh) 編碼方法和系統
PL3523968T3 (pl) Sposoby kodowania i dekodowania oraz odpowiednie urządzenia
SG11202005016SA (en) Nonracemic mixtures and uses thereof
SG11202000907UA (en) Positional tracking and encoding in microfluidic devices
IL274657A (en) Coding and decoding methods and appropriate devices
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
IL264473A (en) GPR156 variants and their uses
IL273671A (en) Cornoline variants and their use
GB201602209D0 (en) Improvements in security devices
IL263682A (en) Antibiotic variants and their uses
EP3659125C0 (en) LOCK AND DEVICE PROVIDED THEREOF
SG11202000566RA (en) Takraw balls
AU2022252803A1 (en) Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
GB201508028D0 (en) Sandfalls and the like
GB201710557D0 (en) Lock and apparatus comprising the same
GB201712268D0 (en) Polypeptides and uses thereof
GB201712266D0 (en) polypeptides and uses thereof
GB201613143D0 (en) Polypeptides and uses thereof
GB201613142D0 (en) Polypeptides and uses thereof